🏅 FDA Orphan Designation
Eloctate
antihemophilic factor (recombinant), Fc fusion protein
Manufacturer: Bioverativ Therapeutics, Inc.
Indicated for:
Moderate hemophilia AOrphan
FDA-Approved Indications (1)
Moderate hemophilia AOrphan Designation
Indicated in adults and children with Hemophilia A (congenital Factor VIII deficiency) for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine proph…
Indications & Usage
Indicated in adults and children with Hemophilia A (congenital Factor VIII deficiency) for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.